Skip to main content
. 2021 Jun 16;46(1):71–80. doi: 10.4093/dmj.2020.0274

Fig. 1.

Fig. 1.

Study design. The participants were randomly assigned to either the Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) or EDITION group and self-titrated the dose of insulin glargine 300 units/mL according to each algorithm for 12 weeks. NIAHA, noninsulin antihyperglycemic agents; NPH, neutral protamine Hagedorn; SMBG, self-monitoring of blood glucose. aIn group 2, one individual was excluded owing to the withdrawal of informed consent.